1. GPCR/G Protein
    Metabolic Enzyme/Protease
    Autophagy
  2. Adenosine Receptor
    Phosphodiesterase (PDE)
    Autophagy

Theophylline (Synonyms: 1,3-Dimethylxanthine; Theo-24)

Cat. No.: HY-B0809 Purity: 99.58%
Data Sheet SDS Handling Instructions

Theophylline is a methylated xanthine derivative; competitive nonselective phosphodiesterase inhibitor and nonselective adenosine receptor antagonist.

For research use only. We do not sell to patients.
Theophylline Chemical Structure

Theophylline Chemical Structure

CAS No. : 58-55-9

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $66 In-stock
5 g $60 In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Theophylline is a methylated xanthine derivative; competitive nonselective phosphodiesterase inhibitor and nonselective adenosine receptor antagonist.

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01684683 The First Affiliated Hospital of Guangzhou Medical University Bronchiectasis November 2012 Phase 4
NCT02080078 AHS Cancer Control Alberta|Cross Cancer Institute Non-small Cell Lung Cancer|Advanced Solid Malignancies September 2014 Phase 1
NCT02023554 Zhujiang Hospital Chronic Obstructive Pulmonary Disease|Asthma December 2013
NCT03015090 XiaoGuang Zou|Southern Medical University, China|Kashgar 1st People's Hospital Chronic Obstructive Pulmonary Disease January 2016
NCT01601132 Takeda Healthy May 2012 Phase 4
NCT02001935 Zhujiang Hospital Chronic Obstructive Pulmonary Disease September 2013
NCT01769898 The First Affiliated Hospital of Guangzhou Medical University Bronchiectasis July 2013 Phase 4
NCT03029429 Vanderbilt University Medical Center|Harvard University Pseudohypoparathyroidism|Albright Hereditary Osteodystrophy December 1, 2017 Phase 2
NCT02463409 Vanderbilt University Medical Center|Massachusetts General Hospital Pseudohypoparathyroidism Type 1a|Albright Hereditary Osteodystrophy June 2015 Phase 2
NCT00983905 Mutual Pharmaceutical Company, Inc. Pharmacokinetics August 2008 Phase 1
NCT00299858 Ottawa Hospital Research Institute|Ontario Lung Association COPD October 2006 Phase 2|Phase 3
NCT01132781 University of East Anglia|Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK) Rhinosinusitis|Asthma|Allergic Rhinitis May 2010 Phase 2
NCT01263106 Eli Lilly and Company Major Depressive Disorder December 2010 Phase 1
NCT02261727 The George Institute|National Health and Medical Research Council, Australia Chronic Obstructive Pulmonary Disease May 2014 Phase 4
NCT02643602 Technische Universität München Radiographic Contrast Agent Nephropathy December 2005
NCT00671151 Hospital Universitari Son Dureta|Fondo de Investigación Sanitaria (FIS)|Sociedad Española de Neumología y Cirugía Torácica COPD June 2005
NCT02184247 Boehringer Ingelheim Healthy April 1998 Phase 1
NCT00779259 Mutual Pharmaceutical Company, Inc. Pharmacokinetics August 2007 Phase 1
NCT02273440 Boehringer Ingelheim Healthy May 2000 Phase 1
NCT01599871 Hospital Son Espases|Spanish Research Center for Respiratory Diseases|Fundación Mutua Madrileña Chronic Obstructive Pulmonary Disease January 2011 Phase 3
NCT01017939 Janssen Research & Development, LLC Prostate Neoplasms January 2010 Phase 1
NCT02088502 Isfahan University of Medical Sciences Contrast-Induced Nephropathy September 2013 Phase 2|Phase 3
NCT00003808 Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|North Central Cancer Treatment Group Leukemia May 1999 Phase 2
NCT00119496 University of Glasgow|GlaxoSmithKline|Chest, Heart and Stroke Association Scotland|Chief Scientist Office of the Scottish Government Asthma July 2005 Phase 2|Phase 3
NCT00003684 NCIC Clinical Trials Group|Canadian Cancer Trials Group Pulmonary Complications|Quality of Life|Unspecified Adult Solid Tumor, Protocol Specific March 1998 Phase 3
NCT01566565 Norwegian Armed Forces Medical Service|Duke University|Oslo University Hospital High Altitude Pulmonary Hypertension March 2012 Phase 1
NCT00492518 Technische Universität München Contrast Induced Nephropathy|Kidney Diseases|Renal Failure|Adverse Effects February 2002 Phase 4
NCT01799161 Eckhard Podack|University of Miami Non-Small Cell Lung Cancer|Non-small-cell Lung Carcinoma|Lung Cancer|NSCLC December 2014 Phase 1
NCT01066728 University of Manitoba|Canadian Institutes of Health Research (CIHR)|The Children's Hospital Foundation of Manitoba Apnea of Prematurity August 2001 Phase 2|Phase 3
NCT02479451 Massachusetts General Hospital End Stage Renal Disease|Olfactory Disorders October 2015 Phase 2
NCT00893009 Assaf-Harofeh Medical Center COPD July 2009
NCT00756418 Merck Sharp & Dohme Corp. Asthma June 2003 Phase 4
NCT01415518 AstraZeneca Chronic Obstructive Pulmonary Disease (COPD) September 2011 Phase 4
NCT01759862 Stanford University Function of Renal Transplant November 2012
NCT02340520 UConn Health COPD December 2014 Phase 3
NCT01010178 Baqiyatallah Medical Sciences University Chronic Obstructive Pulmonary Disease February 2008 Phase 4
NCT01902758 University of Montana Acute Mountain Sickness August 2013 Phase 2|Phase 3
NCT00634413 Pulmagen Therapeutics Chronic Obstructive Pulmonary Disease February 2008 Phase 2
NCT03115294 Tampere University Hospital|Tampere University of Technology Heart Ventricles May 16, 2016
NCT00000578 National Heart, Lung, and Blood Institute (NHLBI)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Asthma|Lung Diseases April 1994 Phase 3
NCT01696214 University of California, San Diego|National Heart, Lung, and Blood Institute (NHLBI) Asthma October 2012 Phase 4
NCT02537691 Hoffmann-La Roche Asthma August 27, 2015 Phase 4
NCT02257463 Mansoura University Chronic Obstructive Pulmonary Disease October 2011
NCT00157937 Merck Sharp & Dohme Corp. Asthma|Allergic Rhinitis February 2003 Phase 4
NCT01293734 Liaoning University of Traditional Chinese Medicine|Shenyang Huanggu District Central Hospital|Benxi City hospital of Chinese medicine|Changda hospital in Anshan city Bronchial Asthma December 2008 Phase 2
NCT00252785 AstraZeneca Asthma October 2005 Phase 3
NCT01794780 Novartis Pharmaceuticals|Novartis COPD February 2013
NCT00252863 AstraZeneca Asthma December 2004 Phase 3
View MoreCollapse
References
Molecular Weight

180.16

Formula

C₇H₈N₄O₂

CAS No.

58-55-9

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: 21 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Theophylline
Cat. No.:
HY-B0809
Quantity: